Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Rituximab Significantly Lessens Myasthenia Gravis Manifestations, Rescue Treatments Needed
November 18th 2022Compared with placebo, a greater proportion of patients on rituximab met the primary end point of minimal disease manifestations at 16 weeks, and demonstrated favorable results on several secondary end points.
NeuroVoices: Timothy Miller, MD, PhD, on the Impact of Tofersen, Antisense Therapeutics in ALS
November 16th 2022The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided perspective on the phase 3 VALOR findings of tofersen, an antisense agent currently under review to treat SOD1-mutated ALS.
Gore Explores Migraine Treatment Using Patent Foramen Ovale Closure in New Study
November 15th 2022The newly announced prospective, randomized, placebo- and sham-controlled study, will include 150 patients, ages 18 to 55 years, with documented patent foramen ovale and a history of more than 1 migraine headache day per week.
Phase 2/3 Results of Zavegepant Showcase Effectiveness as Acute Migraine Medication
November 15th 2022Evidence of therapeutic benefit for zavegepant was observed on multiple secondary end points, including return to normal function at 30 min postdose, sustained pain relief, and sustained pain freedom.
uniQure Receives DSMB Recommendation to Resume Higher Dosing of AMT-130 in Huntington Trial
November 13th 2022The 26-patient trial includes 10 individuals with early-manifest Huntington disease on low-dose AMT-130 and 16 in the high-dose cohort, which will continue enrollment after a DSMB found no further safety concerns.
NurOwn Stromal Cell Therapy Continues to Show Positive Data in Less Severe ALS
November 9th 2022After removing participants at higher risk of reaching a floor effect of the ALSFRS-R, those treated with NurOwn demonstrated a higher rate of clinical response and less function lost across 28 weeks than placebo.
Patient-Reported Outcomes Worsen as ALS Disease Progresses, Real-World Study Shows
November 4th 2022On King’s staging systems, ALSAQ-5 scores increased from 24.6 at stage 1 to 62.1 at stage 4, whereas for Milano-Torino Staging systems, patients’ ALSAQ-5 scores increased from 43.2 at stage 0 to 80.7 at stage 3.
SBT-272 Shows Neuroprotective Impacts in ALS Mouse Models of TDP-43 Pathology
November 2nd 2022SBT-272, an investigational small molecule in development for ALS and other neurological disease of mitochondrial dysfunction, resulted in improved membrane potential and axonal outgrowth of TDP-43 in vitro.